LEOPOLDO
MUÑOZ MEDINA
Ikertzailea 2022-2023 tartean
Juan Antonio
Pineda Vergara
Juan Antonio Pineda Vergara-rekin lankidetzan egindako argitalpenak (10)
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
2020
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
2016
2014
-
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting
HIV Medicine, Vol. 15, Núm. 7, pp. 417-424
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2009
-
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 1, pp. 178-183
2008
-
Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1365-1373
-
Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932